#VisualAbstract: Hepatitis E vaccine shows promising 10-year efficacy in the Chinese population
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at ...
Tag: hepatitis
Hepatitis E vaccine shows promising 10-year efficacy in the Chinese population
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at ...
The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
#VisualAbstract: Resmetirom improves outcomes in patients with nonalcoholic steatohepatitis (NASH) compared to placebo
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Pilot program of chronic hepatitis B treatment in Ethiopia
1. In this pilot program conducted in Ethiopia, researchers demonstrated the long-term benefits and feasibility of treatment for chronic hepatitis ...
#VisualAbstract: Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018
1. The prevalence of Hepatitis C infection during pregnancy increased between 1998 and 2018, coinciding with the opioid epidemic. 2. ...
Trends in the prevalence of Hepatitis C infection during pregnancy and maternal-infant outcomes in the US, 1998 to 2018
1. The prevalence of Hepatitis C infection during pregnancy increased between 1998 and 2018, coinciding with the opioid epidemic. 2. ...
Mortality rates among patients successfully treated for hepatitis C still higher than the general population
1. Among those treated for Hepatitis C Virus (HCV) infection, leading causes of death included drug abuse, liver failure, and ...
Buleviritide reduces viral load in patients with chronic hepatitis D
1. In this randomized controlled trial, 48 weeks of buleviritide treatment resulted in reduced hepatitis D ribonucleic acid (RNA) levels ...
Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
